Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, July 08, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company...
-
A Cambridge-founded medtech company Upfront Diagnostics Announces Global Medical Advisory Board to Accelerate Efforts in Reducing Time to Stroke Care
-
SplashBIO Launches as an Independent Platform Company for Biomarker-Driven Clinical Trial Enrollment
SplashBIO™ brings biomarker pre-screening to the front of the clinical trial — built to reduce screen failures and accelerate enrollment.
-
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028 Company positions...
-
Aclarion Announces Texas Spine Care Center as New CLARITY Site
-
Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub
-
Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform
-
Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal
-
Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting
-
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation